Article

Oxidative-Induced Angiogenesis Is Modulated by Small Extracellular Vesicle miR-302a-3p Cargo in Retinal Pigment Epithelium Cells

Maria Oltra 1,2,*, Miriam Martínez-Santos 1,2,3, María Ybarra 1,2, Hugo Rowland 1, María Muriach 4, Javier Romero 5,*, Javier Sancho-Pelluz 1,2,* and Jorge M. Barcia 1,2

1 Neurophysiology and Neurobiology, School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain; miriam.m.santos@ucv.es (M.M.-S.); mariaybarras98@gmail.com (M.Y.); hurow@mail.ucv.es (H.R.); jm.barcia@ucv.es (J.M.B.)
2 Centro de Investigación Translacional San Alberto Magno, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain
3 Doctoral School, Catholic University of Valencia San Vicente Mártir, 46002 Valencia, Spain
4 School of Health Sciences, University Jaume I, Av. Vicent Sos Baynat, 12006 Castellón de la Plana, Spain; muriach@med.uji.es
5 Hospital General de Requena, Hospital de Requena Calle Casablanca, 46340 Valencia, Spain; romero_fragom@gva.es
* Correspondence: maria.oltra@ucv.es (M.O.); fj.sancho@ucv.es (J.S.-P.)

Abstract: Extracellular vesicles are released from cells under diverse conditions. Widely studied in cancer, they are associated with different diseases playing major roles. Recent reports indicate that oxidative damage promotes the release of small extracellular vesicle (sEVs) from the retinal pigment epithelium (RPE), with an angiogenic outcome and changes in micro-RNA (miRNA) levels. The aim of this study was to determine the role of the miRNA miR-302a-3p, included within RPE-released sEVs, as an angiogenic regulator in cultures of endothelial cells (HUVEC). ARPE-19 cell cultures, treated with H2O2 to cause an oxidative insult, were transfected with a miR-302a-3p mimic. Later, sEVs from the medium were isolated and added into HUVEC or ARPE-19 cultures. sEVs from ARPE-19 cells under oxidative damage presented a decrease of miR-302a-3p levels and exhibited proangiogenic properties. In contrast, sEVs from miR-302a-3p-mimic transfected cells resulted in control angiogenic levels. The results herein indicate that miR-302a-3p contained in sEVs can modify VEGFA mRNA expression levels as part of its antiangiogenic features.

Keywords: microRNAs; small extracellular vesicles; retinal pigment epithelial cells; vasculogenesis

1. Introduction

Environmental cell conditions can promote the release of extracellular vesicles (EVs) [1–4]. EVs can be sub-micro-sized, known as microparticles, or nanometric-sized, previously known as exosomes and currently known as small extracellular vesicles (sEVs) [5–7]. Normally, sEVs can include several molecules in their cargo, such as proteins, lipids, and genetic material, e.g., micro-RNA (miRNA) [8,9]. Current evidence indicates that sEVs can regulate long-distance organs or neighboring cells and modulate tumor progression and metastasis [10–14]. Moreover, sEVs have been pointed out as potential therapeutic molecules and might be key for early diagnosis on different eye-related disorders [15,16].

Lately, miRNA–non-coding, short (around 22 nucleotides), single-stranded RNA molecules have also been highlighted as potential therapeutic tools and diagnostic markers [17–20]. miRNAs are able to interact with mRNA strains, inhibiting them, thus reducing protein expression. They are found inside the cell as well as the extracellular medium, including plasma. Circulating miRNAs might travel free in blood plasma or, as mentioned...
above, as part of the sEVs cargo [21]. This fact has been recently assayed in non-small-cell lung cancer cells by engineering miR-449a as sEVs cargo against the evolution of the disease [22].

It is well described that oxidative insults lead to several responses in many cell types. Concretely, retinal pigment epithelial cells (RPE) are under constant oxidative challenge because of sunlight and high metabolic rate, among others. This circumstance has been pointed out as partially responsible of some proliferative eye-related diseases such as wet age-related macular degeneration (AMD) and diabetic retinopathy (DR) [23]. It has been shown that oxidative stress modifies some VEGF-related miRNAs in ARPE-19 cells, thus promoting angiogenesis [24,25]. In addition, oxidative challenge also promotes excessive sEVs release, which contain some miRNAs—miR-302-a and miR-122—that have been significantly reduced as a consequence of the damage. In contrast, these two miRNAs were unaltered on ARPE-19 cell homogenates [24]. Vascular overproduction is a common trait for different diseases, such as DR, wet AMD, and cancer [26–28]. Therefore, neovascularization is one of the most wanted targets to improve the evolution of such diseases [29–31].

The miR-302-307 cluster is highly expressed in embryonic stem cells in contrast to differentiated cells and regulates cell cycle [32]. MiR-302 cluster inhibits angiogenesis by targeting VEGFA [33] and has also been involved in the reduction of vascular inflammation according to the binding sequence by interaction with zinc finger protein 91 (ZFP91). ZFP91 activates the hypoxia-induced factor 1α (HIF-1 α), promoting cell proliferation [34,35].

All in all, considering the dramatic radical oxygen species (ROS)-induced sEVs release and the paradoxical decreased of miR-302a levels contained on the sEVs [4], we demonstrate herein the vascular influence of the sEVs miR-302a-3p cargo after oxidative challenge on ARPE-19 cells.

2. Materials and Methods

2.1. Cell Culture

The arising retinal pigment epithelium (ARPE-19) human cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). ARPE-19 cells were cultured in Dulbecco’s modified Eagle’s medium/F12 (Invitrogen, Carlsbad, CA, USA), as previously described [24]. Cells were used from 11 to 30 passages. Cells were cultured to 80–90% confluence at a seeding density of 1 × 10⁶ cells/cm². After 48 h of seeding, cells were treated with 600 µM H₂O₂ (Scharlau, Barcelona, Spain) and/or 4 mM N-acetylcysteine (NAC; Sigma-Aldrich, St. Louis, MI, USA) for 24 h grown in media supplemented with 1% of exosome-depleted fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA). Cell media and cells were collected and preserved for future experiments.

Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical veins as previously described [36]. HUVEC were grown in endothelial cell media (PromoCell, Heidelberg, Germany) supplemented with 20% FBS, penicillin/streptomycin, and amphotericin at 37 °C and 5% CO₂.

2.2. Cell Viability

Cell viability as mitochondrial activity was measured using 3′-[1-phenylaminocarbonyl-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benze sulfonic acid hydrate (XTT; Cell Proliferation Kit II; Roche, Basel, Switzerland). ARPE-19 cells were seeded at 6 × 10³ cells per well in a 96-cell culture well plate for 24 h. Cells were rinsed with PBS twice and then were incubated with 0.3 mg/mL of XTT final solution for 6 h at 37 °C in 5% CO₂. Mitochondrial activity was measured by fluorescence multiple reader (Victor X5; Perkin Elmer) at 550 nm.

2.3. Vasculogenesis Assay

Vasculogenesis was performed in Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) as previously described [36]. Briefly, HUVEC were seeded 8 × 10⁴ cells per well in a 96 well plate and then treated with ARPE-19 cell media for 5 h. The different conditions were determined by the conditioned medium used: control media, sEVs from control media, sEVs from mimic-miR-302a-3p transfected-control media, sEVs from 600 µM H₂O₂
media, sEVs from mimic-miR-302a-3p transfected 600 μM H2O2 media and 4 mM NAC media. Matrigel was allowed to solidify overnight at 37 °C. Pictures were taken with an Olympus CKX41 inverted microscope (Olympus, Tokyo, Japan) and recorded by an Olympus DP74 digital camera (Olympus, Tokyo, Japan). Angiogenesis Analyzer for ImageJ was used to analyze the total tube length of the taken images.

2.4. sEVs Isolation

sEVs isolation was performed using the Total Exosome Isolation Reagent from cell culture media (Thermo Fisher Scientific, Waltham, MA, USA). The 2 mL of cell media was centrifuged at 2000 × g for 30 min to remove cells and debris. The supernatant containing the cell-free culture media was mixed with 1 mL of Total Exosome Isolation reagent and incubated overnight at 4 °C. After incubation, the sample was centrifuged at 10,000 × g for 1 h at 4 °C. The pellet was resuspended in cell culture media and stored at −80°C for further analysis.

2.5. sEV Characterization

sEV identity was confirmed by electronic microscopy and a nanoparticle tracking system, NanoSight NS300, as described previously [4].

2.6. Analysis of Pathways and miRNA Target Genes

In silico analysis of miR-302a-3p targets were performed using TargetScanHuman (https://www.targetscan.org/vert_80/; accessed on 4 September 2020) using Tarbase. The pathway analysis in which the detected miRNAs were involved was performed using DIANA TOOLS mirPath v.3 algorithm (http://snf-515788.vm.okeanos.grnet.gr/; accessed on 7 September 2020) [37]. Moreover, the analysis of the pathways regulated by the putative targets of the miRNAs was performed with the FUNRICH software using the gen ontology database. With STRING (https://string-db.org/; accessed on 20 September 2020), the networking of the targets was performed.

2.7. Transfection of miR-302a-3p Mimic

ARPE-19 cells were transfected with miR-302a-3p mirVana® miRNA mimic (Thermo Fisher Scientific, Waltham, MA, USA), and mirVana™ miRNA mimic negative control #1 (Thermo Fisher Scientific, Waltham, MA, USA) as a negative control. The procedure of transfection of miRNA mimic and control was described previously [24]. After 48 h of transfection, ARPE-19 cells and cell culture media were collected for following analysis.

2.8. RNA Isolation from ARPE-19 Cells

Total RNA, including mRNA and miRNA, was isolated using an miRNeasy Mini Kit (Qiagen, Hilden, Germany), as described previously [24]. Total RNA was quantified by NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).

2.9. RNA Isolation from sEVs

RNA from sEVs was isolated using the commercial Total sEVs RNA and Protein Isolation Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. Total RNA was eluted with 50 μL of RNase-free water pre-warmed at 95 °C. The isolated RNA was stored at −80 °C. Quality and quantity of total RNA was measured by NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).

2.10. mRNA Expression Analysis

mRNA expression from ARPE-19 cells was carried out by quantitative real-time PCR (qRT-PCR). Retro transcription reaction of 1000 ng of RNA was performed with SuperScript III First-Strand Synthesis System (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). For qPCR Kicq Start™ Primer (Sigma-Aldrich, St. Louis, MO, USA), Sybr Green Supermix (BioRad, Hercules, CA, USA), and RT-PCR Roche 234 Lighter-
Cycler 480 were used, with the appropriate temperature cycles as described previously [24]. The specific primers for VEGFA were: 5’-TGAAGGTGGAGTGCAACGGAT-3’ (forward) 5’-TCTCTAGCGTGCGTCCCA-3’ (reverse), and for GAPDH were: 5’-GACCTATACGCGGTTCGTCTT-3’ (forward) 5’-AATGTGAATGCAGACCAAAG-3’ (reverse). GAPDH was used as normalizer. Relative expression was calculated as $2^{-\Delta\Delta Ct}$.

2.11. miRNA Expression Analysis

qRT-PCR was performed to assess sEV miRNA expression levels. sEV RNA was retrotranscribed using a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Bedford, MA, USA) using the specific TaqMan RT primer for miR-302a-3p. qPCR was performed using the TaqMan™ microRNA primer for miR-302a-3p (Thermo Fisher Scientific, Waltham, MA, USA) with TaqMan Gene Expression Master Mix (Applied Biosystems, Bedford, MA, USA) and RT-PCR Roche 234 LighterCycler 480, as described by Oltra et al. [24]. RNU6B snoRNA was used as normalizer. Relative expression was calculated as $2^{-\Delta\Delta Ct}$.

2.12. Statistical Analysis

Results of each experiment are presented as mean ± SEM. Each experiment was repeated at least three times. Statistical significance was set at 0.05 using a t-test or ANOVA followed by Tukey’s post hoc test, as appropriate. The statistical analysis was performed using GraphPad Prims 6 software.

3. Results

3.1. $\text{H}_2\text{O}_2$-Induced SEVs Promoted Oxidative Stress, Decreasing Cell Viability in ARPE-19 Cells

$\text{H}_2\text{O}_2$-induced SEVs (see the Materials and Methods section) resulted in significantly increased ROS levels (% DHE) when cultured with naïve ARPE-19 cells. This increase fitted with the observed ARPE-19 cell viability decrease. Both phenomena were significantly reduced by the addition of the antioxidant NAC. sEVs from control ARPE-19 cells resulted in significantly lesser oxidative levels compared to control (Figure 1A) and viability levels equal to control condition (Figure 1B). sEVs were observed using electronic microscopy and quantified by nanoparticle tracking system in order to characterized them (Figure 2).

Figure 1. sEVs induced oxidative stress and affected cell viability. Superoxide anions were measured by DHE after sEV control (87.16 ± 6.23), sEV $\text{H}_2\text{O}_2$ 600 µM (110.5 ± 2.61), and sEV $\text{H}_2\text{O}_2$ 600 µM with N-acetylcysteine exposure (72.03 ± 6.61) (A). XTT assay was performed on the analyzed cell viability after sEV control (97.98 ± 1.58), sEV $\text{H}_2\text{O}_2$ 600 µM (91.38 ± 2.43), and sEV $\text{H}_2\text{O}_2$ 600 µM with N-acetylcysteine exposure (114.8 ± 2.31). (B). Values are expressed as percentage to control ± SEM (n = 4; DHE and n = 3–4; XTT). The p-value was calculated by ANOVA, and statistically significant differences were * $p < 0.05$, ** $p < 0.01$, and **** $p < 0.0001$. 
Figure 1. sEVs induced oxidative stress and affected cell viability. Superoxide anions were measured by DHE after sEV control (87.16 ± 6.23), sEV H2O2 600 µM (110.5 ± 2.61), and sEV H2O2 600 µM with N-acetylcysteine exposure (72.03 ± 6.61) (A). XTT assay was performed on the analyzed cell viability after sEV control (97.98 ± 1.58), sEV H2O2 600 µM (91.38 ± 2.43), and sEV H2O2 600 µM with N-acetylcysteine exposure (114.8 ± 2.31). (B). Values are expressed as percentage to control ± SEM (n = 4; DHE and n = 3–4; XTT). The p-value was calculated by ANOVA, and statistically significant differences were *p < 0.05, **p < 0.01, and ****p < 0.0001.

Figure 2. sEVs released by ARPE-19 cell characterization. sEVs released by control ARPE-19 cells (A) and 600 µM H2O2 ARPE-19 cells (B) were observed by electron microscopy and nanoparticle tracking analysis sEV control (C) and sEVs H2O2 600 µM (D) Scale bar: 200 nm.

3.2. miR-302a-3p Targets and Related Pathways

Networks and biological pathways regulated by the predicted targets were entered into the FUNRICH software (version 3.1.3) to perform the functional analysis. The functional enrichment analysis of miR-302a-3p showed 607 biological processes regulated by at least one of the 1019 mRNA target of miR-302a-3p. Among the top 20 related pathways, 1.3% of genes were related to GTPase activity, dentate gyrus development by 0.7%, and DNA damage response by 3% (Figure 3).

Figure 3. miR-302a-3p protein target-related pathways. Top 20 biological processes regulated by miR-302a-3p predicted targets, using FUNRICH and the Gene Ontology database.
About 38 pathways related to miR-302a-3p mRNA targets are related to blood vessel formation. Using STRING, angiogenic and vasculogenic related processes were selected, and 213 mRNA predicted targets were found, which encode proteins involved in the regulation of angiogenic processes (Figure 4A). Among the most repeated mRNA targets related to vasculogenic processes are VEGFA, EGFR, and AKT1. In fact, in silico analysis showed that VEGFA, EGFR, and AKT1 mRNAs are predicted targets for miR-302a-3p (Figure 4B).

### Figure 4

Angiogenic or vasculogenic pathways regulated by miR-302a-3p mRNA-related targets. Interactional network of miR-302a-3p angiogenic related targets, showing the connected ones (A). Predicted binding site of miR-302a-3p with the 3’UTR mRNA of VEGFA, EGFR, and AKT1 (B).

#### 3.3. VEGFA mRNA and Angiogenesis Were Regulated by H$_2$O$_2$ and SEVs

To assess the effect of sEVs on VEGFA mRNA expression, sEVs from both control and H$_2$O$_2$-treated ARPE-19 cells were isolated and cultured with naïve ARPE-19 cells. We previously reported that VEGFA mRNA was significantly overexpressed in ARPE-19 cells after H$_2$O$_2$ exposure [24]. Similarly, ARPE-19 cells cultured with H$_2$O$_2$-induced sEVs resulted in significantly increased VEGFA mRNA levels compared to control and control-induced sEVs (Figure 5E). In order to demonstrate the role of sEVs in angiogenesis,
HUVEC cultured on standard cell culture medium or with sEVs from control ARPE-19 cells did not result in significant levels of angiogenesis (Figure 5A,B,D). However, cell culture media with H$_2$O$_2$-induced sEVs significantly increased angiogenesis in HUVEC cells (Figure 5C,D).

**Figure 5.** sEV-mediated vasculogenesis. HUVEC tube formation subject to different ARPE-19 cell culture media. Control medium (100 ± 0) (A), control sEVs (117.2 ± 1.79) (B), and sEV H$_2$O$_2$ 600 µM (128.7 ± 9.52) (C). Scale bar: 100 µM. Total length (D) was calculated. mRNA VEGFA expression after 24 h of sEVs control (0.85 ± 0.16) and sEVs H$_2$O$_2$ 600 µM (2.44 ± 0.6) exposure in ARPE-19 cells (E). Values are expressed as mean ± SEM (n = 3; Matrigel assay and n = 5; mRNA expression analysis). The p-value was obtained by ANOVA; * p < 0.05 and ** p < 0.01.

3.4. miR-302a-3p sEV Cargo Regulated Oxidative-Induced Angiogenesis

HUVEC vasculogenic assay was performed to demonstrate the angiogenic effect of miR-302a-3p. HUVEC were grown with sEVs released from ARPE-19 cells under different conditions. Control-released sEVs keep the vascular processes at levels equals to fresh cell culture medium (Figure 6A,B,I). Moreover, sEVs released after miR-302a-3p mimic addition resulted in a significant vascular decrease (Figure 6D,I). As expected, H$_2$O$_2$-induced sEVs significantly increased angiogenic changes (Figure 6F,J). However, these changes were reduced by adding miR-302a-3p mimic (with H$_2$O$_2$ treatment, see the Materials and Methods section) (Figure 6G,J). All the aforementioned changes were normalized by NAC addition, indicating its oxidative nature (Figure 6C,E,G,I,J).
Figure 6. Angiogenesis was mediated by miR-302a-3p within sEVs. HUVEC tube formation subject to different sEVs released by ARPE-19 cell under different conditions. Control medium (100 ± 0) (A), sEVs released in control conditions (91.76 ± 4.5) (B), sEVs released in control conditions and N-acetylcysteine (93.44 ± 7.69) (C), sEVs released in control conditions with mimic miR-302a-3p (84.27 ± 4.15) (D), N-acetylcysteine (90.30 ± 5.61) (E), sEVs released in H2O2 600 µM conditions (118 ± 6.43) (F), sEVs released in H2O2 600 µM conditions and N-acetylcysteine (84.88 ± 6.79) (G), and sEVs released in H2O2 600 µM conditions with mimic miR-302a-3p (80.57 ± 3.52) (H). Total length (I, J) was calculated. Values are expressed as mean ± SEM (n = 3). The p-value was calculated by ANOVA; * p < 0.05, ** p < 0.01, and *** p < 0.001.

3.5. VEGFA mRNA Was Overexpressed by H2O2 and Modulated by miR-302a-3p

In silico analysis indicated miR-302a-3p as a VEGFA target. ARPE-19 VEGFA mRNA expression was determined by qRT-PCR (Figure 7). VEGFA mRNA was significantly overexpressed by both H2O2 sEVs and H2O2 exposure compared to control sEVs and the control. miR-302a-3p mimic exposure significantly decreased the H2O2-induced VEGFA mRNA expression under the control mRNA expression levels. The addition of NAC significantly reduced H2O2-induced VEGFA mRNA expression to control levels.
Figure 7. Proangiogenic molecules regulated by miR-302a-3p within sEVs. After 24h of sEV control (0.49 ± 0.24), sEV control and N-acetylcysteine (1.30 ± 0.14), sEV control and miR-302a-3p mimic (0.49 ± 0.09), H$_2$O$_2$ 600 µM (1.77 ± 0.39), sEVs H$_2$O$_2$ 600 µM (1.94 ± 0.12), sEVs H$_2$O$_2$ 600 µM and N-acetylcysteine (1.27 ± 0.16), sEVs H$_2$O$_2$ 600 µM and miR-302a-3p mimic (0.19 ± 0.07), and N-acetylcysteine (0.68 ± 0.18) exposure the mRNA VEGFA expression was analyzed by q-RT-PCR. Values are expressed as mean ± SEM (n = 4–5). The p-value was calculated by ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

Finally, in order to demonstrate that miR-302a-3p mimic exposure is capable of affecting sEV cargo, we transfected ARPE-19 cells with miR-302a-3p mimic (see the Materials and Methods section), and sEVs were analyzed by qRT-PCR. Our findings strongly indicated that miR-302a-3p mimic transfection resulted in a significantly high miR-302a-3p expression levels on sEVs (Figure 8). This result supports the possibility of a direct targeting of miR-302a-3p on VEGF mRNA.
After seeing NAC results, one can argue that ROS or indirect pro-oxidant molecules were **modulating this “oxidative” condition. H$_2$O$_2$-induced sEVs increased ROS and decreased miR-302a-3p inside the sEVs [4]. Recently, we demonstrated how H$_2$O$_2$ stimulates angiogenesis processes [24]. Here, we demonstrate how the H$_2$O$_2$-induced sEVs can promote angiogenesis similarly to H$_2$O$_2$ exposure.

We previously reported how H$_2$O$_2$ promoted sEVs release on ARPE-19 cells containing significantly low miR-302a levels [4]. In agreement with others, we showed that miR-302a acts as a VEGFA mRNA modulator [33], and it has been shown that miR-302a-3p interacts with ZFP91, activating HIF-1 $\alpha$ (HIF-1 $\alpha$ is a classical VEGFA promoter) [34]. However, results herein indicate that miR-302a-3p directly interacts with VEGFA mRNA. This interaction could explain the vascular modification observed when adding miR-302a-3p mimic (Figure 6). On this line, and in agreement with our results, miR-302d and miR-302a were already considered as direct VEGFA mRNA modulators on HeLa and leukemia cells [42,43]. Similarly, VEGFA mRNA can also be directly modulated by miR-205 in glioblastoma cells or ARPE-19 cells [24,44]. These findings strongly suggest that different miRNAs can directly modulate VEGFA mRNA according to cell type origin such as miR-526b-3p, miR-150-5p, and miR-410, among others [45–47].

One of the first noteworthy aspects is that H$_2$O$_2$-induced sEVs are capable of transmitting this “oxidative” condition. H$_2$O$_2$-induced sEVs increased ROS and decreased ARPE-19 cell viability. This fact matches with other studies that showed that the oxidative insult modulates the number of sEVs released and the nature of their cargo [1,4,39–41]. After seeing NAC results, one can argue that ROS or indirect pro-oxidant molecules are included as sEVs cargo. NAC was administered to ARPE-19 treated with H$_2$O$_2$-induced sEVs cultures, resulting in ROS level reduction. In addition, this process was accompanied by significantly decreased miR-302a-3p inside the sEVs [4]. Recently, we demonstrated how H$_2$O$_2$ stimulates angiogenesis processes [24]. Here, we demonstrate how the H$_2$O$_2$-induced sEVs can promote angiogenesis similarly to H$_2$O$_2$ exposure.

After seeing NAC results, one can argue that ROS or indirect pro-oxidant molecules were **modulating this “oxidative” condition. H$_2$O$_2$-induced sEVs increased ROS and decreased miR-302a-3p inside the sEVs [4]. Recently, we demonstrated how H$_2$O$_2$ stimulates angiogenesis processes [24]. Here, we demonstrate how the H$_2$O$_2$-induced sEVs can promote angiogenesis similarly to H$_2$O$_2$ exposure.
In order to demonstrate the role of miR-302a-3p in angiogenesis, we transfected ARPE-19 cells with a miR-302a-3p mimic on the different experimental conditions. The results indicate a marked negative regulation of miR-302a-3p on VEGFA mRNA expression levels/angiogenesis. H2O2-induced sEVs transfected with miR-302a-3p mimic resulted in reduced level of angiogenesis/VEGFA mRNA expression. This finding again fits with the suggestion of a direct miR-302a-3p/VEGFA mRNA binding as a mechanism of action. Interestingly, sEVs from H2O2-treated ARPE-19 cells significantly increase angiogenesis and VEGFA mRNA expression compared to control-treated cells. This agrees with previous data from our lab indicating that oxidative stress significantly decreases miR-302a-3p levels in sEVs, compared to control [4], thus providing support to the anti-angiogenic role of miR-302a-3p. Furthermore, it is well characterized that oxidative stress can promote angiogenic drive [48–50]. VEGFA is upregulated by ROS through the PI3K/Akt pathway [51]. The addition of the antioxidant NAC to stressed condition normalized the increased VEGF mRNA/angiogenesis levels, suggesting it as an oxidative-dependent event.

In conclusion, oxidative stress promotes sEV release with pro-angiogenic properties. The angiogenic effect is inhibited by miR-302a-3p and promoted by ROS. The mechanism of action seems to be related to the topological homology between VEGFA mRNA and miR-302a-3p. This opens a new strategy against oxidative-induced angiogenesis by promoting miR-302a-3p as a VEGFA mRNA repressor.

Author Contributions: Conceptualization, M.O. and J.M.B.; methodology, M.O. and M.M.-S.; formal analysis, M.O., M.M.-S., M.Y. and J.S.-P.; investigation, M.O., M.M.-S., M.Y. and J.S.-P.; writing—original draft preparation, M.O. and J.M.B.; English editing, H.R., J.S.-P. and J.M.B.; writing—review and editing, J.R., M.M. and J.S.-P.; funding acquisition, J.M.B. and J.S.-P.; supervision, J.M.B. and J.S.-P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Agencia Estatal de Investigación (AEI), grant number PID2020-117875GB-I00/AEI/ 10.13039/501100011033, and Instituto de Salud Carlos III (ISCIII), grant number PI21/00083. Internal funds from the Centro de Investigación Traslacional San Alberto Magno (CITSAM) from Universidad Católica de Valencia San Vicente Mártir (UCV) were also used.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Atienzar-Aroca, S.; Flores-Bellver, M.; Serrano-Heras, G.; Martinez-Gil, N.; Barcia, J.M.; Aparicio, S.; Perez-Cremades, D.; García-Verdugo, J.M.; Diaz-Llopis, M.; Romero, F.J.; et al. Oxidative Stress in Retinal Pigment Epithelium Cells Increases Exosome Secretion and Promotes Angiogenesis in Endothelial Cells. *J. Cell Mol. Med.* 2016, 20, 1457–1466. [CrossRef]
2. Biasutti, L.; Chiechi, A.; Couch, R.; Liotta, L.A.; Espina, V. Retinal Pigment Epithelium (RPE) Exosomes Contain Signaling Phosphoproteins Affected by Oxidative Stress. *Exp. Cell Res.* 2013, 319, 2113–2123. [CrossRef] [PubMed]
3. Freeman, D.W.; Noren Hooten, N.; Eitan, E.; Green, J.; Mode, N.A.; Bodogai, M.; Zhang, Y.; Lehrmann, E.; Zonderman, A.B.; Biragyn, A.; et al. Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes. *Diabetes* 2018, 67, 2377–2388. [PubMed] [CrossRef]
4. Oltra, M.; Vidal-Gil, L.; Maisto, R.; Oltra, S.S.; Romero, F.J.; Sancho-Pelluz, J.; Barcia, J.M. MiR302a and 122 Are Deregulated in Small Extracellular Vesicles from ARPE-19 Cells Cultured with H2O2. *Sci. Rep.* 2019, 9, 17954. [CrossRef] [PubMed]
5. Greening, D.W.; Simpson, R.J. Understanding Extracellular Vesicle Diversity–Current Status. *Expert Rev. Proteomics* 2018, 15, 887–910. [PubMed] [CrossRef]
6. van Niel, G.; D’Angelo, G.; Raposo, G. Shedding Light on the Cell Biology of Extracellular Vesicles. *Nat. Rev. Mol. Cell. Biol.* 2018, 19, 213–228. [CrossRef] [PubMed]
7. Thiery, C.; Wittwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. *J. Extracell. Vesicles* 2018, 7, 1535750. [CrossRef]
8. Rashid, M.H.; Bayraktar, E.; Helal, G.K.; Abd-Elah, M.F.; Amero, P.; Chavez-Reyes, A.; Rodriguez-Aguayo, C. Exosomes: From Garbage Bins to Promising Therapeutic Targets. *Int. J. Mol. Sci.* 2017, 18, 538. [CrossRef]
9. Kao, C.Y.; Papoutsakis, E.T. Extracellular Vesicles: Exosomes, Microparticles, Their Parts, and Their Targets to Enable Their Biomanufacturing and Clinical Applications. *Curr. Opin. Biotechnol.* 2019, 60, 89–98. [CrossRef]

10. Chen, Y.; Xu, Y.; Zhong, H.; Yuan, H.; Liang, F.; Liu, J.; Tang, W. Extracellular Vesicles in Inter-kingdom Communication in Gastrointestinal Cancer. *Cancer Treat. Rev.* 2021, 11, 1087–1103. [CrossRef]

11. Chen, W.; Li, Z.; Deng, P.; Li, Z.; Xu, Y.; Li, H.; Su, W.; Qin, J. Advances of Exosomal MiRNAs in Breast Cancer Progression and Diagnosis. *Diagn. Histol. Pathol.* 2021, 11, 2151. [CrossRef] [PubMed]

12. Faić, S.; Muller, J.; De Veirman, K.; De Bruyne, E.; Maes, K.; Vrancen, L.; Heusschen, R.; De Raeye, H.; Schots, R.; Vanderkerken, K.; et al. Exosomes Play a Role in Multiple Myeloma Bone Disease and Tumor Development by Targeting Osteoclasts and Osteoblasts. *Blood Cancer J.* 2018, 8, 4494. [CrossRef]

13. Waldenmaier, M.; Seibold, T.; Seufferlein, T.; Eiseler, T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short-and Long-Distance Communication. *Cancers* 2021, 13, 4844. [CrossRef] [PubMed]

14. Qiao, Z.; Zhang, Y.; Ge, M.; Liu, S.; Jiang, X.; Shang, Z.; Liu, H.; Cao, C.; Xiao, H. Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway. *Cancer Treat. Rev.* 2019, 18, 1619–1629. [CrossRef] [PubMed]

15. Zhang, Z.; Liang, X.; Zhou, J.; Meng, M.; Gao, Y.; Yi, G.; Fu, M. Exosomes in the Pathogenesis and Treatment of Ocular Diseases. *Exp. Eye Res.* 2021, 209, 108626. [CrossRef] [PubMed]

16. Shah, N.; Ishii, M.; Brandon, C.; Ablonczy, Z.; Cai, J.; Liu, Y.; Chou, C.J.; Rohrer, B. Extracellular Vesicle-Mediated Long-Range Communication in Stressed Retinal Pigment Epithelial Cell Monolayers. *Biochem. Biophys. Acta Mol. Basis Dis.* 2018, 1864, 2610–2622. [CrossRef] [PubMed]

17. Greco, M.; Chiefari, E.; Accattato, F.; Corigliano, D.M.; Arcidiacono, B.; Mirabelli, M.; Liguori, R.; Brunetti, F.S.; Pullano, S.A.; Scorcia, V.; et al. Microrna-1281 as a Novel Circulating Biomarker in Patients with Diabetic Retinopathy. *Front. Endocrinol.* 2020, 11, 1–12. [CrossRef]

18. Li, X.; Yu, Z.W.; Wang, Y.; Fu, Y.H.; Gao, X.Y. MicroRNAs: Potential Targets in Diabetic Retinopathy. *Horm. Metab. Res.* 2020, 52, 142–148. [CrossRef]

19. Ren, C.; Liu, Q.; Wei, Q.; Cai, W.; He, M.; Du, Y.; Xu, D.; Wu, Y.; Yu, J. Circulating MiRNAs as Potential Biomarkers of Age-Related Macular Degeneration. *Cell Physiol. Biochem.* 2017, 41, 1413–1423. [CrossRef] [PubMed]

20. Ingenito, F.; Roscigno, G.; Affinito, A.; Nuzzo, S.; Scognamiglio, I.; Quintavalle, C.; Condorelli, G. The Role of Exo-MiRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. *Int. J. Mol. Sci.* 2019, 20, 4687. [CrossRef]

21. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-Mediated Transfer of MRNAs and MicroRNAs as a Novel Mechanism of Genetic Exchange between Cells. *Nat. Cell Biol.* 2007, 9, 654–669. [CrossRef] [PubMed]

22. Zhou, W.; Xu, M.; Wang, Z.; Yang, M. Engineered Exosomes Loaded with MiR-449a Selectively Inhibit the Growth of Homologous Non-Small Cell Lung Cancer. *Cancer Cell Int.* 2021, 21, 485. [CrossRef] [PubMed]

23. Flores-Bellver, M.; Mighty, J.; Aparicio-Domingo, S.; Li, K.V.; Shi, C.; Zhou, J.; Cobb, H.; McGrath, P.; Michelis, G.; Lenhart, P.; et al. Extracellular Vesicles Released by Human Retinal Pigment Epithelium Mediate Increased Polarised Secretion of Drusen Proteins in Response to AMD Stressors. *J. Extracell. Vesicles* 2021, 10, e12165. [CrossRef] [PubMed]

24. Oltra, M.; Vidal-Gil, L.; Maisto, R.; Sancho-Pelluz, J.; Barcia, J.M. Oxidative Stress-Induced Angiogenesis Is Mediated by MiR-205-5p. *J. Cell Mol. Med.* 2020, 24, 1428–1436. [CrossRef] [PubMed]

25. Yoon, C.; Kim, D.; Kim, S.; Park, G.B.; Hur, D.Y.; Yang, J.W.; Park, S.G.; Kim, Y.S. MiR-9 Regulates the Post-Transcriptional Level of VEGF165a by Targeting SRPK-1 in ARPE-19 Cells. *Graefes Arch.* 2018, 256, 3565–3566. [CrossRef] [PubMed]

26. Smith, G.A.; Fearnley, G.W.; Harrison, M.A.; Tomlinson, D.C.; Wheatcroft, S.B.; Ponnambalam, S. Vascular Endothelial Growth Factor A (VEGF-A) in Coronary Artery Disease. *J. Cell Mol. Med.* 2020, 14, 2151. [CrossRef] [PubMed]

27. Smith, G.A.; Fearnley, G.W.; Harrison, M.A.; Tomlinson, D.C.; Wheatcroft, S.B.; Ponnambalam, S. Vascular Endothelial Growth Factor A (VEGF-A) in Coronary Artery Disease. *J. Cell Mol. Med.* 2020, 14, 2151. [CrossRef] [PubMed]

28. Ricci, F.; Bandello, F.; Navarra, P.; Staurenghi, G.; Stump, M.; Zarbin, M. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. *Int. J. Mol. Sci.* 2020, 21, 8242. [CrossRef] [PubMed]

29. Farnoodian, M.; Wang, S.; Dietz, J.; Nickells, R.W.; Sorenson, C.M.; Sheibani, N. Negative Regulators of Angiogenesis: Important Targets for Treatment of Exudative AMD. *Clin. Sci.* 2017, 131, 1763–1780. [CrossRef] [PubMed]

30. Winkler, F.; Osswald, M.; Wick, W. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. *J. Clin. Immunol.* 2020, 41, 181–186. [CrossRef]

31. Song, Y.; Fu, Y.; Xie, Q.; Zhu, B.; Wang, J.; Zhang, B. Anti-Angiogenic Agents in Combination with Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. *Front. Immunol.* 2020, 11, 1956. [CrossRef] [PubMed]

32. Barroso-del Jesus, A.; Lucena-Aguilar, G.; Menendez, P. The MiR-302-367 Cluster as a Potential Stemness Regulator in ESCs. *Cell Cycle* 2009, 8, 394–398. [CrossRef] [PubMed]

33. Cao, J.; Li, L.; Han, X.; Cheng, H.; Chen, W.; Qi, K.; Chen, C.; Wu, Q.; Niu, M.; Zeng, L.; et al. MiR-302 Cluster Inhibits Angiogenesis and Growth of K562 Leukemia Cells by Targeting VEGFA. *Onco. Targets Ther.* 2019, 12, 433–441. [CrossRef] [PubMed]

34. Ma, J.; Mi, C.; Wang, K.S.; Lee, J.J.; Jin, X. Zinc Finger Protein 91 (ZFP91) Activates HIF-1α via NF-KB/P65 to Promote Proliferation and Tumorigenesis of Colon Cancer. *Oncotarget* 2016, 7, 36551–36562. [CrossRef] [PubMed]
35. Yuan, J.N.; Hong, Y.; Ma, Z.L.; Pang, R.P.; Lei, Q.Q.; Lv, X.F.; Zhou, J.G.; Huang, H.; Zhang, T.T. MiR-302a Limits Vascular Inflammation by Suppressing Nuclear Factor-κB Pathway in Endothelial Cells. *Front. Cell Dev. Biol*. 2021, 9, 682574. [CrossRef] [PubMed]

36. Bueno-Betí, C.; Novella, S.; Lázaro-Franco, M.; Pérez-Cremades, D.; Heras, M.; Sanchis, J.; Hermenegildo, C. An Affordable Method to Obtain Cultured Endothelial Cells from Peripheral Blood. *J. Cell Mol. Med*. 2013, 17, 1475–1483. [CrossRef]

37. Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-MiRPath v3.0: Deciphering MicroRNA Function with Experimental Support. *Nucleic Acids Res*. 2015, 43, W460–W466. [CrossRef] [PubMed]

38. Park, J.E.; Tan, H.S.; Datta, A.; Lai, R.C.; Zhang, H.; Meng, W.; Lim, S.K.; Sze, S.K. Hypoxic Tumor Cell Modulates Its Microenvironment to Enhance Angiogenic and Metastatic Potential by Secretion of Proteins and Exosomes. *Mol. Cell Proteom.* 2010, 9, 1085–1099. [CrossRef] [PubMed]

39. Chiaradia, E.; Tancini, B.; Emiliani, C.; Delo, F.; Pellegrino, R.M.; Tognoloni, A.; Urbanelli, L.; Buratta, S. Extracellular Vesicles under Oxidative Stress Conditions: Biological Properties and Physiological Roles. *Cells* 2021, 10, 1763. [CrossRef]

40. Takasugi, M.; Okada, R.; Takahashi, A.; Virya Chen, D.; Watanabe, S.; Hara, E. Small Extracellular Vesicles Secreted from Senescent Cells Promote Cancer Cell Proliferation through EphA2. *Nat. Commun.* 2017, 8, 15729. [CrossRef]

41. Qi, H.; Wang, Y.; Fa, S.; Yuan, C.; Yang, L. Extracellular Vesicles as Natural Delivery Carriers Regulate Oxidative Stress Under Pathological Conditions. *Front. Bioeng. Biotechnol.* 2021, 9, 752019. [CrossRef] [PubMed]

42. Cao, W.; Zhao, Y.; Wang, L.; Huang, X. Circ0001429 Regulates Progression of Bladder Cancer through Binding MiR-205-5p and Promoting VEGFA Expression. *Cancer Biomark*. 2019, 25, 101–113. [CrossRef] [PubMed]

43. Hua, Z.; Lv, Q.; Ye, W.; Wong, C.K.A.; Cai, G.; Gu, D.; Ji, Y.; Zhao, C.; Wang, J.; Yang, B.B.; et al. MiRNA-Directed Regulation of VEGF and Other Angiogenic Factors under Hypoxia. *PLoS ONE* 2006, 1, e116. [CrossRef]

44. Yue, X.; Wang, P.; Xu, J.; Zhu, Y.;Sun, G.; Fang, Q.; Tao, R. MicroRNA-205 Functions as a Tumor Suppressor in Human Glioblastoma Cells by Targeting VEGF-A. *Oncol. Rep.* 2012, 27, 1200–1206. [CrossRef] [PubMed]

45. Zhang, L.; Liu, L.; Li, X. MiR-526b-3p Mediates Doxorubicin-Induced Cardiotoxicity by Targeting STAT3 to Inactivate VEGFA. *Biomed. Pharmacother*. 2020, 123, 109751. [CrossRef] [PubMed]

46. Qin, Y.; Zhang, B.; Ge, B.J. MicroRNA-150-5p Inhibits Proliferation and Invasion of Osteosarcoma Cells by down-Regulating VEGFA. *Eur. Rev. Med. Pharmacol. Sci*. 2020, 24, 9265–9273.

47. Chen, N.; Wang, J.; Hu, Y.; Cui, B.; Li, W.; Xu, G.; Liu, L.; Liu, S. MicroRNA-410 Reduces the Expression of Vascular Endothelial Growth Factor and Inhibits Oxygen-Induced Retinal Neovascularization. *PLoS ONE* 2014, 9, e95665. [CrossRef]

48. Kim, Y.W.; Byzova, T.V. Oxidative Stress in Angiogenesis and Vascular Disease. *Blood* 2014, 123, 625–631. [CrossRef]

49. Kim, Y.W.; West, X.Z.; Byzova, T.V. Inflammation and Oxidative Stress in Angiogenesis and Vascular Disease. *J. Mol. Med.* 2013, 91, 323–328. [CrossRef]

50. Wang, S.; Ji, L.Y.; Li, L.; Li, J.M. Oxidative Stress, Autophagy and Pyroptosis in the Neovascularization of Oxygen-induced Retinopathy in Mice. *Mol. Med. Rep.* 2019, 19, 927–934.

51. Kosmidou, I.; Xagorari, A.; Roussos, C.; Papapetropoulos, A. Reactive Oxygen Species Stimulate VEGF Production from C(2)C(12) Skeletal Myotubes through a PI3K/Akt Pathway. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 2001, 280, L585–L592. [CrossRef] [PubMed]